AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $45.09.
Several equities analysts recently commented on the stock. Wedbush reissued an "outperform" rating and issued a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday. Guggenheim cut their price target on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a report on Thursday, August 15th. HC Wainwright cut shares of AnaptysBio from a "buy" rating to a "neutral" rating and decreased their price target for the company from $52.00 to $19.00 in a research report on Wednesday. Finally, BTIG Research lowered AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd.
Read Our Latest Stock Report on AnaptysBio
Insider Buying and Selling at AnaptysBio
In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares of the company's stock, valued at approximately $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last quarter. 33.70% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On AnaptysBio
A number of large investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. purchased a new stake in AnaptysBio during the 3rd quarter valued at $49,000. nVerses Capital LLC raised its position in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC lifted its holdings in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock worth $89,000 after buying an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after buying an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd raised its holdings in shares of AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company's stock valued at $205,000 after acquiring an additional 5,342 shares in the last quarter.
AnaptysBio Trading Down 3.2 %
Shares of ANAB traded down $0.49 during midday trading on Thursday, reaching $15.02. The stock had a trading volume of 814,061 shares, compared to its average volume of 379,749. The firm has a market cap of $457.04 million, a PE ratio of -2.47 and a beta of -0.11. The firm has a 50 day simple moving average of $25.93 and a 200-day simple moving average of $29.48. AnaptysBio has a one year low of $14.20 and a one year high of $41.31.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, research analysts forecast that AnaptysBio will post -6.02 EPS for the current fiscal year.
About AnaptysBio
(
Get Free ReportAnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Read More
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.